Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.
Oncology, Medical October 9th 2023
Cancer Therapy Advisor
Discover how local therapy options like radiotherapy and radical prostatectomy can significantly improve overall survival rates in cN1 prostate cancer patients.
OBR Oncology
The increasing acquisition of oncology practices by private equity firms poses new challenges to healthcare ethics and operations. Stay informed and be prepared to advocate for patient-centric reforms.
Hematology/Oncology October 9th 2023
The Epoch Times
Discover the emerging evidence on the cancer risks associated with commonly prescribed medications and what it means for your prescribing habits.
Discover how the FDA-approved Invitae’s Common Hereditary Cancers Panel can enhance your approach to early cancer detection and personalized treatment planning.
The New England Journal of Medicine
Explore the intricate relationship between stem cell self-renewal and precancer states to better understand its implications for future cancer therapies